163 related articles for article (PubMed ID: 16126738)
1. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?
Duric VM; Stockler MR; Heritier S; Boyle F; Beith J; Sullivan A; Wilcken N; Coates AS; Simes RJ
Ann Oncol; 2005 Nov; 16(11):1786-94. PubMed ID: 16126738
[TBL] [Abstract][Full Text] [Related]
2. Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.
Duric VM; Butow PN; Sharpe L; Boyle F; Beith J; Wilcken NR; Heritier S; Coates AS; John Simes R; Stockler MR
Psychooncology; 2007 Jan; 16(1):48-59. PubMed ID: 16856128
[TBL] [Abstract][Full Text] [Related]
3. Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer.
Duric VM; Butow PN; Sharpe L; Heritier S; Boyle F; Beith J; Wilcken NR; Coates AS; Simes RJ; Stockler MR
Patient Educ Couns; 2008 Aug; 72(2):239-45. PubMed ID: 18434070
[TBL] [Abstract][Full Text] [Related]
4. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?
Simes RJ; Coates AS
J Natl Cancer Inst Monogr; 2001; (30):146-52. PubMed ID: 11773309
[TBL] [Abstract][Full Text] [Related]
5. Patients' and doctors' preferences for adjuvant chemotherapy in resected non-small-cell lung cancer: What makes it worthwhile?
Blinman P; Hughes B; Crombie C; Christmas T; Hudson M; Veillard AS; Muljadi N; Millward M; Wright G; Flynn P; Windsor M; Stockler M; McLachlan SA;
Eur J Cancer; 2015 Aug; 51(12):1529-37. PubMed ID: 26059196
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?
Blinman P; Duric V; Nowak AK; Beale P; Clarke S; Briscoe K; Boyce A; Goldstein D; Hudson M; Stockler M
Eur J Cancer; 2010 Jul; 46(10):1800-7. PubMed ID: 20137908
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
8. Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
; Blinman P; Mileshkin L; Khaw P; Goss G; Johnson C; Capp A; Brooks S; Wain G; Kolodziej I; Veillard AS; O'Connell R; Creutzberg CL; Stockler MR
Br J Cancer; 2016 Nov; 115(10):1179-1185. PubMed ID: 27764842
[TBL] [Abstract][Full Text] [Related]
9. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile.
Duric V; Stockler M
Lancet Oncol; 2001 Nov; 2(11):691-7. PubMed ID: 11902540
[TBL] [Abstract][Full Text] [Related]
10. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
12. Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
Duric VM; Fallowfield LJ; Saunders C; Houghton J; Coates AS; Stockler MR
Br J Cancer; 2005 Dec; 93(12):1319-23. PubMed ID: 16333242
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
14. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
[TBL] [Abstract][Full Text] [Related]
15. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
16. Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
Leone JP; Leone J; Vallejo CT; Pérez JE; Romero AO; Machiavelli MR; Romero Acuña L; Domínguez ME; Langui M; Fasce HM; Leone BA; Ortiz E; Iturbe J; Zwenger AO
Breast Cancer Res Treat; 2014 Jan; 143(2):313-23. PubMed ID: 24327333
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
Vaz-Luis I; O'Neill A; Sepucha K; Miller KD; Baker E; Dang CT; Northfelt DW; Winer EP; Sledge GW; Schneider B; Partridge AH
Cancer; 2017 Aug; 123(15):2821-2828. PubMed ID: 28323331
[TBL] [Abstract][Full Text] [Related]
20. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
